EC
Highly rated in
34
conditions

Dr. Edwin Choy

Massachusetts General Hospital
Boston, MA
Highly rated in
34
conditions
Specialties:Oncology | Hematology Oncology
Experience:23 Years
Clinical Trials:Currently Recruiting for 3 Trials
Accepts:New PatientsMedicare
Highly rated in
34
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. Edwin Choy's experience treating your condition:
About Dr. Edwin Choy

Edwin Choy is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Choy has been practicing medicine for over 23 years and is highly rated in 34 conditions, according to our data. His top areas of expertise are Adult Soft Tissue Sarcoma, Osteosarcoma, Liposarcoma, Bone Tumor, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Choy is currently accepting new patients.

His clinical research consists of co-authoring 149 peer reviewed articles and participating in 16 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Edwin Choy it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Edwin Choy accepts the following insurance:

  •  Ambetter
  •  Anthem
Call to see if your plan is accepted.
Locations
55 Fruit St, Boston, MA 02114
Background & Education
Graduate Institution
New York University School Of Medicine, 2000
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Wentworth-Douglass Hospital
Brigham And Womens Hospital
Massachusetts General Hospital
Cooley Dickinson Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T Cells in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Genetic
Study Phase: Phase 2
SARC041: Phase 3 Randomized Double-Blind Study of Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma
Enrollment Status: Recruiting
Publish Date: October 07, 2022
Intervention Type: Drug
Study Phase: Phase 3
Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma or Rhabdomyosarcoma Following Failure of Prior Chemotherapy
Enrollment Status: Recruiting
Publish Date: October 29, 2021
Intervention Type: Drug
Study Drugs: OlaparibTemozolomideIrinotecan
Study Phase: Phase 1
A Phase II Trial of Sitravatinib (MGCD516), a Multi-receptor Tyrosine Kinase Inhibitor, in Advanced Liposarcoma and Other Soft Tissue Sarcomas
Enrollment Status: Active, not recruiting
Publish Date: November 28, 2022
Intervention Type: Drug
Study Drug: MGCD516
Study Phase: Phase 2
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
Enrollment Status: Active, not recruiting
Publish Date: November 16, 2022
Intervention Type: Drug
Study Drugs: EribulinPembrolizumab
Study Phase: Phase 2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Enrollment Status: Active, not recruiting
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drugs: Letetresgene AutoleucelFludarabineCyclophosphamide
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Active, not recruiting
Publish Date: October 20, 2022
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
Phase 2 Trial of Palbociclib and Ganitumab in Patients With Relapsed or Refractory Ewing Sarcoma
Enrollment Status: Active, not recruiting
Publish Date: September 19, 2022
Intervention Type: Drug
Study Drugs: PalbociclibGanitumab
Study Phase: Phase 2
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug
Study Drug: Tegavivint
Study Phase: Phase 1
Phase I Trial of Bevacizumab, Metronomic Doxorubicin and Radiation Therapy for Resectable Soft Tissue Sarcoma
Enrollment Status: Active, not recruiting
Publish Date: April 07, 2022
Intervention Type: Drug, Radiation
Study Drugs: BevacizumabDoxorubicin
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Active, not recruiting
Publish Date: December 07, 2021
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
Phase I Study of Nilotinib Given With Radiation For Patients With High Risk Chordoma
Enrollment Status: Active, not recruiting
Publish Date: October 29, 2021
Intervention Type: Radiation, Drug
Study Drug: Nilotinib
Study Phase: Phase 1
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally-advanced or Metastatic NY-ESO-1+ Synovial Sarcoma Participants Following First Line Systemic Anti-cancer Therapy (V943-003, IMDZ-04-1702)
Enrollment Status: Terminated
Publish Date: April 16, 2020
Intervention Type: Biological, Other
Study Phase: Phase 3
A Phase II Study of Mocetinostat Administered With Gemcitabine for Patients With Metastatic Leiomyosarcoma With Progression or Relapse Following Prior Treatment With Gemcitabine-Containing Therapy
Enrollment Status: Completed
Publish Date: January 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of the PARP Inhibitor, Olaparib, in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy
Enrollment Status: Completed
Publish Date: May 19, 2017
Intervention Type: Drug
Study Phase: Phase 2
Phase I/II Study of PCI-24781 in Combination With Doxorubicin for Treatment of Advanced Sarcomas Following Failure or Prior Anthracycline Therapy
Enrollment Status: Completed
Publish Date: February 14, 2017
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials -
149 Total Publications
NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: November 09, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
DD
Daniel J. Deangelo
Dr. Daniel J. Deangelo
Oncology | Hematology Oncology
Highly rated in
38
conditions
Oncology
Hematology Oncology

Dana-Farber Cancer Institute

450 Brookline Ave, 
Boston, MA 
 2.7 mi

Daniel Deangelo is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Deangelo has been practicing medicine for over 30 years and is highly rated in 38 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Systemic Mastocytosis, Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Deangelo is currently accepting new patients.

MD
Dr. Matthew S. Davids
Oncology | Hematology Oncology
Highly rated in
26
conditions
Oncology
Hematology Oncology

Dana-Farber Cancer Institute, Medical Oncology

450 Brookline Ave, 
Boston, MA 
 2.7 mi

Matthew Davids is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Davids has been practicing medicine for over 18 years and is highly rated in 26 conditions, according to our data. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Massachusetts. Davids is currently accepting new patients.

LW
Lori J. Wirth
Dr. Lori J. Wirth
Oncology | Hematology Oncology
Highly rated in
24
conditions
Oncology
Hematology Oncology

Mass General Brigham

Mass General Cancer Center

55 Fruit St, 
Boston, MA 

Lori Wirth is an Oncologist and a Hematologist Oncology expert in Boston, Massachusetts. Wirth has been practicing medicine for over 26 years and is highly rated in 24 conditions, according to our data. Her top areas of expertise are Medullary Thyroid Carcinoma, Thyroid Cancer, Anaplastic Thyroid Cancer, Papillary Thyroid Cancer, and Tissue Biopsy. She is licensed to treat patients in Massachusetts. Wirth is currently accepting new patients.